Eli Lilly has unveiled new late-stage trial data showing its weight-loss pill Foundayo delivered double-digit weight reduction in adults aged 65 and older — a key demographic considered difficult to treat safely with obesity medicines.

The new post-hoc analysis from the Phase 3 ATTAIN-1 and ATTAIN-2 trials, presented at ECO 2026 in Istanbul, found that patients aged 65 and above lost as much as 13% of their body weight after 72 weeks on the highest dose of Foundayo (orforglipron).

The results strengthen Lilly’s push into the booming obesity market with what it says is the only approved GLP-1 pill that can be taken at any time of day without food or water restrictions.

In the ATTAIN-1 study, which enrolled adults with obesity or overweight but without type 2 diabetes, patients aged 65 and older recorded average weight reductions of 7.9% on the 5.5 mg dose, 11.3% on the 9 mg dose and 13% on the 17.2 mg dose, compared with 1.6% for placebo.

In ATTAIN-2, which included adults with obesity or overweight and type 2 diabetes, older patients lost 7.5%, 8.3% and 12.2% across the three dose groups, versus 2.3% for placebo.

The company said all doses achieved statistically significant reductions in body weight compared with placebo at 72 weeks.

“Weight management in older adults requires careful consideration of both benefit and risk. These data are reassuring on both fronts —up to 13% weight loss was observed in patients 65 and older taking Foundayo, with a safety profile similar to what was observed in the broader trial populations,” said Rachel Batterham, senior vice president of medical innovation, Lilly Cardiometabolic Health.

“The fact that these results were achieved with a once-daily pill that patients can take at any time, without planning around meals or dealing with injections, matters in this age group.”

The safety profile was broadly consistent across age groups, Lilly said, with gastrointestinal side effects including nausea, constipation, diarrhea and vomiting reported most frequently — effects commonly associated with GLP-1 drugs.

Serious adverse events were higher among older adults than younger participants but remained generally in line with expectations for the drug class. Among participants aged 65 and older, pooled serious adverse events were reported in 9.9%, 13.0% and 11.6% of patients across the three dose groups, compared with 11.4% in the placebo arm.

Foundayo, approved by the FDA for chronic weight management, is part of a rapidly expanding class of GLP-1 obesity therapies reshaping the pharmaceutical industry. Unlike injectable rivals, the once-daily pill does not require fasting or meal timing restrictions, a feature Lilly is positioning as a major convenience advantage.

The ATTAIN-1 trial enrolled 3,127 adults globally, including 195 participants aged 65 and older, while ATTAIN-2 enrolled 1,613 adults, including 418 in the older age group. Both studies evaluated three once-daily doses of orforglipron against placebo over 72 weeks, alongside diet and exercise interventions.